Innovative Study Design

Learn more

Clinical Trials Execution

Learn more

Data Analysis Center

Learn more

Event Adjudication

Learn more

HCRI designs and runs clinical trials with world-class academic researchers and industry sponsors. We combine the logistical capabilities of a contract research organization with world-class academic scientific leadership.

We have a proven track record in cardiology, central nervous system, and pulmonology, and our research and publications show it.

Extended DAPT After PCI May Be Best in Patients With, Without ACS.

Medscape (3/25, Busko, 201K) reports that research indicated that “compared with stopping dual antiplatelet therapy (DAPT) at 12 months, extending therapy to 30 months reduced the risk of stent thrombosis and MI but also increased the risk of mild to moderate bleeding in patients who had a coronary stent implanted—whether this followed an initial MI or stable angina.” .

Patients with Atrial Fibrillation and PCI or ACS Need Triple Therapy - Practical Guidance

HCRI's Executive Director, Cardiometabolic Trials, Christopher Cannon presents the need for triple therapy in patients with AFib and PCI or ACS at ACC 2015.

What are injectable cholesterol drugs and are they right for you?

Dr. Christopher Cannon discusses a new kind of cholesterol lowering drug.

On The Scene Video - ACC 2015 - Dr. Robert Yeh

Dr. Robert Yeh discusses the DAPT Trial results in patients presenting with versus without acute coronary syndromes at ACC 2015

Dual Antiplatelet Therapy Beyond One Year in Patients Receiving Coronary Stents for Treatment of Acute Coronary Syndromes

Dr. Robert Yeh presents on the Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients with and without Myocardial Infarction at ACC 2015.